Awawu Igbinadolor
Adolescent Medicine · Monroe, NCNPI 1386658128
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 29.7% of the total. Reporting peaked in 2024 at $3,264 and has fallen 99.5% since, to $15 in 2025. Among adolescent medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $61.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$2K
- Novartis$1K
- Modernatx, Inc.$1K
- Novo Nordisk$538
- AstraZeneca$285
- Merz North America, Inc.$278
- plus $1K from 18 others
Across 2,115 payments — averaging $10,795 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$12.6M
- Alnylam Pharmaceuticals Inc.$3M
- Modernatx, Inc.$1.9M
- Pfizer$1.7M
- Novartis$767K
- Johnson & Johnson$531K
- plus $2.4M from 20 others
What the payments were for
- Travel & lodging$3,30247%
- Food & beverage$3,64352%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 7 | $2,070 |
| Novartis | 7 | $1,273 |
| Modernatx, Inc. | 5 | $1,118 |
| Novo Nordisk | 27 | $538 |
| AstraZeneca | 17 | $285 |
| Merz North America, Inc. | 2 | $278 |
| Amgen(2 entities) | 2 | $242 |
| Bayer | 9 | $201 |
| Abbott | 7 | $132 |
| Viiv Healthcare Company | 1 | $125 |
| Johnson & Johnson | 1 | $107 |
| Gilead | 1 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $104 |
| Boehringer Ingelheim | 5 | $89 |
| GSK | 4 | $65 |
| Lilly USA, LLC | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $60 |
| AbbVie | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Merck | 1 | $14 |
| Alk-abello, Inc | 1 | $13 |
| Pfizer | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,981 in reported general payments places this provider in the 95th percentile of 52 adolescent medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $47,702 |
| RybelsusSemaglutide | 22 | $32,241 |
| JardianceEmpagliflozin | 47 | $32,012 |
| JanuviaSitagliptin Phosphate | 14 | $10,741 |
| LinzessLinaclotide | 14 | $7,209 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,233 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $962 |
| Colchicine | 25 | $852 |
| Diclofenac Sodium | 27 | $694 |
| Omeprazole | 59 | $680 |
| Azelastine Hcl | 14 | $506 |
| Losartan Potassium | 49 | $505 |
| Atorvastatin Calcium | 115 | $459 |
| Levothyroxine Sodium | 49 | $431 |
| Fluticasone Propionate | 25 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $538 | $79,94265 claims |
| Boehringer IngelheimJardiance | $89 | $32,01247 claims |
| MerckJanuvia | $14 | $10,74114 claims |
| AbbVieLinzess | $44 | $7,20914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adolescent medicine providers in North Carolina.
Other adolescent medicine in Monroe
- Juliana ClarkRaleigh$2K
- Joseph OkoyeCharlotte$2K
- Katie LowryLumberton$2K
- Joseph BellPembroke$2K
- Steven HammelClyde$1K
- Najla AhmedShelby$1K
- Benjamin CraigheadSalisbury$1K
- Christopher MagrytaSalisbury$1K
- Danielle RoseSalisbury$973
- Jennifer HudsonSalisbury$951
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.